The development of human monoclonal antibodies against Zika virus

Abstract Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that causes severe neurological complications that include congenital abnormalities and Guillain-Barre syndrome. So far, no effective vaccine or therapy against ZIKV is available. Development of therapeutic antibodies and drugs is an urgent area of research. For flavivirus infections, neutralizing antibodies are the essential components of protective immunity in humans. Recently, much effort has been spent on screening for antibodies that target different epitopes. Verification of the epitope information is important not only for the development of antibody-based therapy but also for the structure-based vaccine design against ZIKV infection in humans. In this chapter, we review the development of human antibodies according to their targeting epitopes.